Treatment of Reactive Arthritis with Biological Agents.

IF 5.7 2区医学 Q1 RHEUMATOLOGY

Current Rheumatology Reports Pub Date : 2024-12-01 Epub Date: 2024-09-23 DOI:10.1007/s11926-024-01165-6

Avarna Agarwal, Debashis Maikap, Prasanta Padhan

{"title":"Treatment of Reactive Arthritis with Biological Agents.","authors":"Avarna Agarwal, Debashis Maikap, Prasanta Padhan","doi":"10.1007/s11926-024-01165-6","DOIUrl":null,"url":null,"abstract":"Purpose of the review: Reactive arthritis (ReA) is an inflammatory joint condition triggered by an infection elsewhere in the body, and this review aims to provide a comprehensive synthesis of recent studies including case reports and case series to determine whether biologics are a treatment option.Recent findings: Recent studies indicate that biological agents, including anti-TNF agents (infliximab, adalimumab, etanercept), anti-IL17 (secukinumab), and anti-IL6 (tocilizumab), are effective in treating refractory cases of ReA. Evidence suggests these agents are associated with significant clinical improvement. Notably, the data reveal that these biologics are generally well-tolerated, with a low incidence of major adverse events, which supports their safety profile for use in ReA. Biological agents, including anti-TNF, anti-IL17, and anti-IL6 therapies, can be safely and effectively used in the treatment of ReA when conventional therapies fail. It further emphasizes the need for a well-designed controlled trial to provide scientific basis for better informed clinical decisions in cases not responding to conventional treatment.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"450-458"},"PeriodicalIF":5.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Rheumatology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11926-024-01165-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of the review: Reactive arthritis (ReA) is an inflammatory joint condition triggered by an infection elsewhere in the body, and this review aims to provide a comprehensive synthesis of recent studies including case reports and case series to determine whether biologics are a treatment option.

Recent findings: Recent studies indicate that biological agents, including anti-TNF agents (infliximab, adalimumab, etanercept), anti-IL17 (secukinumab), and anti-IL6 (tocilizumab), are effective in treating refractory cases of ReA. Evidence suggests these agents are associated with significant clinical improvement. Notably, the data reveal that these biologics are generally well-tolerated, with a low incidence of major adverse events, which supports their safety profile for use in ReA. Biological agents, including anti-TNF, anti-IL17, and anti-IL6 therapies, can be safely and effectively used in the treatment of ReA when conventional therapies fail. It further emphasizes the need for a well-designed controlled trial to provide scientific basis for better informed clinical decisions in cases not responding to conventional treatment.

查看原文本刊更多论文

用生物制剂治疗反应性关节炎。

综述的目的：反应性关节炎（ReA）是一种由身体其他部位感染引发的关节炎症，本综述旨在全面综述包括病例报告和系列病例在内的最新研究，以确定生物制剂是否是一种治疗选择：最近的研究表明，生物制剂，包括抗肿瘤坏死因子制剂（英夫利昔单抗、阿达木单抗、依那西普）、抗IL17（secukinumab）和抗IL6（tocilizumab），对治疗难治性ReA病例有效。有证据表明，这些药物可显著改善临床症状。值得注意的是，数据显示这些生物制剂的耐受性普遍良好，主要不良事件的发生率较低，这支持了它们用于 ReA 的安全性。生物制剂，包括抗肿瘤坏死因子、抗IL17和抗IL6疗法，可在常规疗法失败后安全有效地用于治疗ReA。该研究进一步强调，对于常规治疗无效的病例，有必要进行精心设计的对照试验，为做出更明智的临床决策提供科学依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Rheumatology Reports RHEUMATOLOGY-

CiteScore

11.20

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published research in the field of rheumatology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of rheumatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas such as the many forms of arthritis, osteoporosis and metabolic bone disease, and systemic lupus erythematosus. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also occasionally provided.